News

PROLOR Biotech, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.

Rosetta Genomics announces that a peer-reviewed article entitled "Accurate Molecular Classification of Renal Tumors Using MicroRNA Expression" has been published in the online version of The Journal of Molecular Diagnostics. The study demonstrates the ability of microRNAs to accurately identify four histological types of renal tumors, namely clear cell, papillary, and chromophobe renal cell carcinoma, as well as oncocytoma, a benign tumor.
The study is available online at: http://jmd.amjpathol.org/cgi/content/abstract/jmoldx.2010.090187v1

BiondVax Pharmaceuticals’ Multimeric-001 Universal Flu Vaccine was found to be safe and to activate both arms of the human immune system in a trial of 60 older adult participants

The Company strengthened its balance sheet with the successful completion of a registered direct offering in January 2010 of 2,530,000 ordinary shares and warrants to purchase 1,265,000 ordinary shares at an exercise price of $2.50 per share, with net proceeds to the Company of approximately $4.65 million.

Data Show PROLOR’s Biobetter Form of hGH has Potential to Reduce Required
Dosing Frequency from One Injection Per Day to Two Injections Per Month